In our study, we observed differences in the expression levels of various immune checkpoint molecules, including PDCD1, CD86, and CD47, between the high and low-risk groups, indicating that colon cancer patients in the two risk groups may exhibit different responses to ICIs. Here, PDCD1 is linked to malignant colon neoplasm.